



Amicus Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology

September 26, 2018

CRANBURY, N.J., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview and fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Oncology in New York, NY on Tuesday, October 2, 2018 at 1:00 p.m. ET.

A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at <http://ir.amicusrx.com/events-and-presentations>, and will be archived for 90 days.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company's website at www.amicusrx.com.

Investors:

Amicus Therapeutics
Andrew Faughnan
Associate Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media / Multimedia Assets:

Pure Communications
Jennifer Paganelli
jpaganelli@purecommunications.com
(347) 658-8290

FOLD-G



Source: Amicus Therapeutics, Inc.